Format

Send to

Choose Destination
Expert Rev Clin Immunol. 2015 Mar;11(3):349-61. doi: 10.1586/1744666X.2015.1010517. Epub 2015 Feb 5.

Emerging biologics for the treatment of chronic rhinosinusitis.

Author information

1
The Upper Airways Research Laboratory, Department of Otorhinolaryngology, Ghent University Hospital, Ghent, Belgium.

Abstract

Chronic rhinosinusitis (CRS) is a prevalent chronic inflammatory disease of the nasal and paranasal cavities and is known to seriously impair quality of life in affected patients. CRS appears to be a heterogeneous group of diseases with different inflammatory and remodeling patterns, suggesting that not only different clinical phenotypes but also pathophysiological endotypes occur. CRS with nasal polyps (CRSwNP) is considered a more severe phenotype, especially when associated with comorbid asthma, as patients having this condition often do not respond to conventional treatment, including topical and systemic corticosteroids or surgery. Recently, studies with biologic agents have shown various effects in severe airway disease; specifically in Th2-biased CRSwNP, these effects were very promising. The greatest challenge for the future is to define the different endotypes of CRSwNP using easily accessible biomarkers to select the patients who have the best chance of a positive therapeutic response to innovative approaches.

KEYWORDS:

asthma; biologics; biomarkers; chronic rhinosinusitis; dupilumab; endotypes; mepolizumab; monoclonal antibodies; nasal polyps; omalizumab

PMID:
25651905
DOI:
10.1586/1744666X.2015.1010517
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center